Physiological and Pharmacological Control of BAK, BAX, and Beyond

Trends in Cell Biology

Volumn 26, Issue 12, 2016, Pages 906-917

  Luna Vargas, Mark P A ^a   Chipuk, Jerry Edward ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; BCL 2 family; BH3 mimetics; mitochondria; mitochondrial outer membrane permeabilization

Indexed keywords

BH3 PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; CELL MEMBRANE PERMEABILITY; CONFORMATIONAL TRANSITION; HUMAN; MITOCHONDRION; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; AMINO ACID SEQUENCE; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MODELS, BIOLOGICAL;

EID: 84995578647     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2016.07.002     Document Type: Review

References (83)

1. 1 Newmeyer, D.D., et al. Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 79 (1994), 353–364.
2. 2 Hu, Q., et al. Molecular determinants of caspase-9 activation by the Apaf-1 apoptosome. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 16254–16261.
3. 3 Riedl, S.J., Salvesen, G.S., The apoptosome: signalling platform of cell death. Nat. Rev. Mol. Cell Biol. 8 (2007), 405–413.
4. 4 Chipuk, J.E., et al. The BCL-2 family reunion. Mol. Cell 37 (2010), 299–310.
5. 5 Luna-Vargas, M.P., Chipuk, J.E., The deadly landscape of pro-apoptotic BCL-2 proteins in the outer mitochondrial membrane. FEBS J., 2015 http://dx.doi.org/10.1111/febs.13624.
6. 6 Chipuk, J.E., Green, D.R., How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol. 18 (2008), 157–164.
7. 7 Llambi, F., et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell 44 (2011), 517–531.
8. 8 Doerflinger, M., et al. BH3-only proteins: a 20-year stock-take. FEBS J. 282 (2015), 1006–1016.
9. 9 Letai, A., et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 (2002), 183–192.
10. 10 Lessene, G., et al. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 7 (2008), 989–1000.
11. 11 Petros, A.M., et al. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 1644 (2004), 83–94.
12. 12 Chipuk, J.E., et al. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 20327–20332.
13. 13 Kuwana, T., et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 17 (2005), 525–535.
14. 14 Sarosiek, K.A., et al. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol. Cell 51 (2013), 751–765.
15. 15 Edwards, A.L., et al. Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. Chem. Biol. 20 (2013), 888–902.
16. 16 Dai, H., et al. Evaluation of the BH3-only protein Puma as a direct Bak activator. J. Biol. Chem. 289 (2014), 89–99.
17. 17 Chen, H.C., et al. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat. Cell Biol. 17 (2015), 1270–1281.
18. 18 Du, H., et al. BH3 domains other than Bim and Bid can directly activate Bax/Bak. J. Biol. Chem. 286 (2011), 491–501.
19. 19 O'Neill, K.L., et al. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. Genes. Dev. 30 (2016), 973–988.
20. 20 Follis, A.V., et al. Pin1-induced proline isomerization in cytosolic p53 mediates BAX activation and apoptosis. Mol. Cell 59 (2015), 677–684.
21. 21 Follis, A.V., et al. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nat. Chem. Biol. 9 (2013), 163–168.
22. 22 Khacho, M., et al. Mitochondrial dynamics impacts stem cell identity and fate decisions by regulating a nuclear transcriptional program. Cell Stem Cell, 2016 http://dx.doi.org/10.1016/j.stem.2016.04.015.
23. 23 Buck, M.D., et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell 166 (2016), 63–76.
24. 24 Serasinghe, M.N., et al. Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. Mol. Cell 57 (2015), 521–536.
25. 25 Kashatus, J.A., et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol. Cell 57 (2015), 537–551.
26. 26 Renault, T.T., et al. Mitochondrial shape governs BAX-induced membrane permeabilization and apoptosis. Mol. Cell 57 (2015), 69–82.
27. 27 Kuwana, T., et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111 (2002), 331–342.
28. 28 Lucken-Ardjomande, S., et al. Contributions to Bax insertion and oligomerization of lipids of the mitochondrial outer membrane. Cell Death Differ. 15 (2008), 929–937.
29. 29 Iverson, S.L., et al. Cardiolipin is not required for Bax-mediated cytochrome c release from yeast mitochondria. J. Biol. Chem. 279 (2004), 1100–1107.
30. 30 Schafer, B., et al. Mitochondrial outer membrane proteins assist Bid in Bax-mediated lipidic pore formation. Mol. Biol. Cell. 20 (2009), 2276–2285.
31. 31 Chipuk, J.E., et al. Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell 148 (2012), 988–1000.
32. 32 Shamas-Din, A., et al. Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax. Biochem. J. 467 (2015), 495–505.
33. 33 Raemy, E., et al. Cardiolipin or MTCH2 can serve as tBID receptors during apoptosis. Cell Death Differ. 23 (2016), 1165–1174.
34. 34 Lucken-Ardjomande, S., et al. Bax activation and stress-induced apoptosis delayed by the accumulation of cholesterol in mitochondrial membranes. Cell Death Differ. 15 (2008), 484–493.
35. 35 Martinez-Abundis, E., et al. A CRAC-like motif in BAX sequence: relationship with protein insertion and pore activity in liposomes. Biochim. Biophys. Acta 1808 (2011), 1888–1895.
36. 36 Montero, J., et al. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 68 (2008), 5246–5256.
37. 37 Perera, M.N., et al. Bax and Bcl-xL exert their regulation on different sites of the ceramide channel. Biochem. J. 445 (2012), 81–91.
38. 38 Ganesan, V., et al. Ceramide and activated Bax act synergistically to permeabilize the mitochondrial outer membrane. Apoptosis. 15 (2010), 553–562.
39. 39 Siskind, L.J., et al. The BCL-2 protein BAK is required for long-chain ceramide generation during apoptosis. J. Biol. Chem. 285 (2010), 11818–11826.
40. 40 Subburaj, Y., et al. Bax monomers form dimer units in the membrane that further self-assemble into multiple oligomeric species. Nat. Commun., 6, 2015, 8042.
41. 41 Zhang, Z., et al. BH3-in-groove dimerization initiates and helix 9 dimerization expands Bax pore assembly in membranes. EMBO J. 35 (2016), 208–236.
42. 42 Landeta, O., et al. Minimalist model systems reveal similarities and differences between membrane interaction modes of MCL1 and BAK. J. Biol. Chem. 290 (2015), 17004–17019.
43. 43 Bleicken, S., et al. cBid, Bax and Bcl-xL exhibit opposite membrane remodeling activities. Cell Death Dis., 7, 2016, e2121.
44. 44 Montessuit, S., et al. Membrane remodeling induced by the dynamin-related protein Drp1 stimulates Bax oligomerization. Cell 142 (2010), 889–901.
45. 45 Vela, L., Marzo, I., Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside. Curr. Opin. Pharmacol. 23 (2015), 74–81.
46. 46 Deng, J., et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12 (2007), 171–185.
47. 47 Ni Chonghaile, T., et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334 (2011), 1129–1133.
48. 48 Hartman, M.L., Czyz, M., [BH3 mimetics as a strategy to complement anticancer therapies]. Postepy Hig. Med. Dosw. (Online) 66 (2012), 67–77.
49. 49 Oltersdorf, T., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005), 677–681.
50. 50 Parrondo, R., et al. ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. PeerJ, 1, 2013, e144.
51. 51 Serasinghe, M.N., et al. Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance. Oncogene 34 (2015), 857–867.
52. 52 Rudin, C.M., et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18 (2012), 3163–3169.
53. 53 Peirs, S., et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 124 (2014), 3738–3747.
54. 54 Cohen, N.A., et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem. Biol. 19 (2012), 1175–1186.
55. 55 Leverson, J.D., et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis., 6, 2015, e1590.
56. 56 Gavathiotis, E., et al. Direct and selective small-molecule activation of proapoptotic BAX. Nat. Chem. Biol. 8 (2012), 639–645.
57. 57 Hauck, P., et al. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol. Cancer Ther. 8 (2009), 883–892.
58. 58 Tse, C., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68 (2008), 3421–3428.
59. 59 Souers, A.J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19 (2013), 202–208.
60. 60 Nguyen, M., et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 19512–19517.
61. 61 Wang, W.Q., et al. Gossypol-induced differentiation in human leukemia HL-60 cells. Int. J. Biomed. Sci. 2 (2006), 395–401.
62. 62 Song, T., et al. Pan-BH3 mimetic S1 exhibits broad-spectrum antitumour effects by cooperation between Bax and Bak. Basic Clin. Pharmacol. Toxicol. 113 (2013), 145–151.
63. 63 Kitada, S., et al. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 111 (2008), 3211–3219.
64. 64 Sun, Y., et al. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biol. Ther. 7 (2008), 1418–1426.
65. 65 Wei, J., et al. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J. Med. Chem. 53 (2010), 4166–4176.
66. 66 Sarkar, S., et al. Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic. Oncoimmunology, 5, 2016, e1078059.
67. 67 Zeitlin, B.D., et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res. 66 (2006), 8698–8706.
68. 68 Kazi, A., et al. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. J. Biol. Chem. 286 (2011), 9382–9392.
69. 69 Bai, L., et al. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PloS ONE, 9, 2014, e99404.
70. 70 Cao, X., et al. The novel BH3 alpha-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak. Mol. Cancer, 12, 2013, 42.
71. 71 Doi, K., et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J. Biol. Chem. 287 (2012), 10224–10235.
72. 72 Friberg, A., et al. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J. Med. Chem. 56 (2013), 15–30.
73. 73 Lessene, G., et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 9 (2013), 390–397.
74. 74 Tao, Z.F., et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med. Chem. Lett. 5 (2014), 1088–1093.
75. 75 Dutta, S., et al. Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL. J. Mol. Biol. 427 (2015), 1241–1253.
76. 76 Hsu, S.Y., et al. Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc. Natl. Acad. Sci. U.S.A. 94 (1997), 12401–12406.
77. 77 Inohara, N., et al. Mtd, a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-XL. J. Biol. Chem. 273 (1998), 8705–8710.
78. 78 Beroukhim, R., et al. The landscape of somatic copy-number alteration across human cancers. Nature 463 (2010), 899–905.
79. 79 Carpio, M.A., et al. BCL-2 family member BOK promotes apoptosis in response to endoplasmic reticulum stress. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), 7201–7206.
80. 80 Ke, F., et al. BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice. Cell Death Differ. 19 (2012), 915–925.
81. 81 Llambi, F., et al. BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-associated degradation. Cell 165 (2016), 421–433.
82. 82 Schulman, J.J., et al. The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage. J. Biol. Chem. 288 (2013), 25340–25349.
83. 83 Einsele-Scholz, S., et al. Bok is a genuine multi-BH-domain protein that triggers apoptosis in the absence of Bax and Bak and augments drug response. J. Cell Sci., 2016.